Inflammatory Bowel Disease Management during the COVID-19 Pandemic: A Literature Review.
Middle East J Dig Dis
; 14(2): 155-166, 2022 Apr.
Article
in English
| MEDLINE | ID: covidwho-2044373
ABSTRACT
BACKGROUND:
Coronavirus disease 2019 (COVID-19) caused a global pandemic. Since its start, widespread safety measures have been adopted by nations worldwide. Crohn's disease (CD) and ulcerative colitis are two forms of inflammatory bowel disease (IBD). IBD is a common inflammatory illness with a high worldwide incidence. Its clinical symptoms include stomach discomfort, diarrhea, anorexia, and weight loss. Genetics, microbes, cigarette smoking, appendectomy, lack of personal hygiene, using anti-inflammatory agents, vitamin D deficiency, and stress are the main risk factors for IBD. COVID-19 pandemic raised concerns about the exacerbation of COVID clinical manifestations in patients with IBD and increasing the risk of mortality. During COVID-19 pandemic, intestinal inflammation, and promoting adherence need to be controlled using medications and vaccinations as a primary goal. In this review, we reviewed unique concerns about IBD risk in the population as well as management of the disease, and the effectiveness of vaccination during COVID-19 pandemic.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Experimental Studies
/
Observational study
/
Prognostic study
/
Reviews
Topics:
Vaccines
Language:
English
Journal:
Middle East J Dig Dis
Year:
2022
Document Type:
Article
Affiliation country:
Mejdd.2022.269
Similar
MEDLINE
...
LILACS
LIS